Oncothyreon Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 49   

Articles published

ONTY 1.92 +0.08 (4.35%)
price chart
Why Biotech Stocks Jumped? - BioCryst Pharmaceuticals, Inc. (BCRX ...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) and Oncothyreon Inc (USA) (NASDAQ:ONTY) following small-cap stocks higher. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) extended gains as ...
Related articles »  
Stocks Roundup - Oncothyreon Inc (USA) (NASDAQ:ONTY), SPYGLASS ...
Oncothyreon Inc (USA) (NASDAQ:ONTY)closed latest trading day at $1.71, down-3.39%, on volume of over 673,426shares. Its average trading volume is 833,792shares.
Oncothyreon Announces Third Quarter 2014 Financial Results Conference Call
Oncothyreon Inc. ONTY, +4.35% today announced that it will conduct a conference call on Thursday, November 6, 2014 at 4:30 p.m.
Related articles »  
Shareholder Update: Xplore Technologies (XPLR), Oncothyreon (ONTY), Waters ...
In the eyes of analysts at H.C. Wainwright, Oncothyreon Inc (USA) (NASDAQ:ONTY) is a stock worth buying now. The analysts initiated the stock with a �Buy� recommendation and issued $4 target price on it.
Investor News: TG Therapeutics, Digital Ally, Oncothyreon, Open Text Corp  Markets Insider
Oncothyreon Coverage Initiated at HC Wainwright (ONTY)  Ticker Report
Related articles »  
Oncothyreon Inc - Market Review
NEW YORK (AVAFIN) -- Options traders were heavily trading options contracts during the market session establishing a new 3-month volume record for shares of Oncothyreon Inc. A total of 3,905 put and 3,020 calls were traded equating to a 1.29 put/call ...
Related articles »  
Oncothyreon Receives Average Rating of "Buy" from Analysts (NASDAQ:ONTY)
Finally, analysts at Wedbush initiated coverage on shares of Oncothyreon in a research note on Tuesday, October 21st. They set a �buy� rating and a $4.00 price target on the stock.
Microcap Stocks Lagged: Endocyte (NASDAQ:ECYT), Oncothyreon Inc ...
On September 22, 2014, in connection with the public offering of 10,000 shares of the Company's Series A Convertible Preferred Stock, Oncothyreon Inc. (NASDAQ:ONTY) designated 10,000 shares of its authorized and unissued preferred stock as Series A ...
Related articles »  
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed ...
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY ...
Related articles »  
Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock ...
SEATTLE, Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the pricing of previously announced concurrent but separate underwritten offerings of 10,000,000 shares of its Common Stock at a price to the public of $2.00 per ...
Related articles »  
Recent Investment Analysts' Ratings Updates for Oncothyreon (ONTY)
Oncothyreon is now covered by analysts at Wedbush. They set a �buy� rating and a $4.00 price target on the stock. They wrote, �We are initiating coverage of Oncothyreon Inc. with a Buy rating and a 12-month target price of $4, based on a risk-adjusted ...